There are currently 66 active clinical trials seeking participants for Esophageal Cancer research studies. The states with the highest number of trials for Esophageal Cancer participants are Ohio, Illinois, California and Michigan.
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
NCT04354064
Recruiting
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
Register for Updates
Esophageal Cancer Risk Registry
NCT00260585
Recruiting
The purpose of this study is to identify markers in the blood and tissue that could indicate risk factors for the development and progression of esophagus cancer. This research aims to collect medical history, blood, and tissue samples from patients who present with an esophageal disorder. Identifying genetic and behavioral risk factors involved in the development of esophageal cancer might allow for early detection and prevention. Survival and an opportunity for a cure with esophageal cancer wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/13/2025
Locations: Department of Cardiothoracic Surgery, Pittsburgh, Pennsylvania
Conditions: Esophageal Cancer, Gastroesophageal Reflux Disease (GERD), Esophageal Diseases, Hiatal Hernia, Esophageal Achalasia
Register for Updates
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
NCT00260559
Recruiting
To assess short and long term outcomes after minimally invasive esophagectomy compared to open esophagectomy. To compare both standard outcome measures as well as patient derived outcome measures, in particular, quality of life (QOL). To look at the applicability of this QOL instrument to this patient group.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/13/2025
Locations: University of Pittsburgh Medical Center - Department of Cardiothoracic Surgery, Pittsburgh, Pennsylvania +1 locations
Conditions: Esophagectomy, Esophageal Cancer
Register for Updates
Mayo Clinic Upper Digestive Disease Survey
NCT02530983
Recruiting
The Mayo Clinic Conduit Report Card Questionnaires have been created in order to have a consistent evaluation tools for patients undergoing esophageal reconstruction or treatment or patients that are experiencing an upper digestive disease in order to standardize and validate outcome measures. Data will be used to establish the validation of the questionnaires/survey. Data will also lead to the establishment of "normal" or expected scores for patients undergoing each type of esophagectomy proced... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Esophageal Neoplasms, Cancer of Esophagus, Cancer of the Esophagus, Esophageal Cancer, Esophagus Cancer, Neoplasm, Esophageal, Esophagectomy, Abnormalities, Digestive System, Digestive System Abnormalities
Register for Updates
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT05183126
Recruiting
The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Breast Cancer, Metastatic Gastric Cancer, Esophageal Cancer
Register for Updates
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab for Patients Who Are Disease Free After Completion of Trimodality Treatment for HER-2+ Cancers of Esophagus & Gastroesophageal Junction
NCT05480384
Recruiting
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who have completed chemoradiation followed by esophagectomy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Weill Cornell Medicine/New York-Presbyterian, New York, New York +1 locations
Conditions: Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer
Register for Updates
Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas
NCT05565417
Recruiting
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find the recommended dose of IMT-009 that can be safely given to participants * Learn more about the side effects of IMT-009 * Learn more about pharmacokinetics of IMT-009 * Learn more about the effectiveness of IMT-009 * Learn more about different pharmac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Site 9618, Tucson, Arizona +9 locations
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
Register for Updates
TREAT-BE Study (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)
NCT02634645
Recruiting
A prospective outcomes study in patients with and esophageal cancer (EAC) and Barrett's esophagus (BE) associated neoplasia being evaluated for endoscopic eradication therapy (EET).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/25/2025
Locations: UCLA Medical Center, Los Angeles, California +3 locations
Conditions: Barrett's Esophagus, Esophageal Cancer
Register for Updates
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples from Colorectal Cancer Patients
NCT00899626
Recruiting
RATIONALE: Studying samples of tissue, blood, urine, stool, and other biological fluids from patients with cancer and from healthy volunteers undergoing colonoscopy or endoscopy may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is looking at gastrointestinal biomarkers in tissue and biological fluid samples from patients and participants undergoing colonoscopy, endoscopy, or surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Veterans Affairs Medical Center - Nashville, Nashville, Tennessee +1 locations
Conditions: Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Precancerous Condition
Register for Updates
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
NCT05517811
Recruiting
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with vi... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/27/2025
Locations: University of Colorado Denver, Aurora, Colorado
Conditions: Liver Cancer, Esophageal Cancer, Colorectal Cancer, Lung Adenocarcinoma, Control, Pancreas Cancer, Biliary Cancer
Register for Updates
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835
Recruiting
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: UCSD, La Jolla, California +44 locations
Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Register for Updates
EsophaCap for the Detection of Early Esophageal Carcinoma
NCT04214119
Recruiting
This study is to identify potential biomarkers for the early detection of Barrett's Esophagus, esophageal carcinoma (both adenocarcinoma and squamous cell carcinoma), and gastric cancer via sponge cytology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: Bayview Medical Center, Baltimore, Maryland +1 locations
Conditions: Barrett Esophagus, Esophageal Cancer, Gastric Cancer
Register for Updates